DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ispronicline
Ispronicline
Nicotinic Receptors in Neurodegeneration
R2 ∞
(19) United States (12) Patent Application Publication (10) Pub
Evidence of Efficacy for TC-1734 (AZD3480) in the Treatment of Cognitive Impairment in Older Subjects Geoffrey C
San Antonio, Texas La Quinta Inn and Suites Medical Center 3-4 March
WO 2016/001643 Al 7 January 2016 (07.01.2016) P O P C T
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Pharmaceutical Appendix to the Tariff Schedule 2
Selective Α4β2 Nicotinic Acetylcholine Receptor Agonists Target
2 Agonist ABT-894 in Adults with ADHD
Cognitive Enhancers
Drug Delivery System for Use in the Treatment Or Diagnosis of Neurological Disorders
Activities of Nicotinic Acetylcholine Receptors Modulate Neurotransmission and Synaptic Architecture
Adaptive, Dose-Finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease
3518.Full.Pdf
Stembook 2018.Pdf
Nachr Agonist-Induced Cognition Enhancement: Integration of Cognitive and Neuronal Mechanisms
Botulinum Toxin
Top View
WO 2015/150957 Al 8 October 2015 (08.10.2015) P O P C T
TARGACEPT, INC. (Exact Name of Registrant As Specified in Its Charter)
Cognitive Enhancement As a Pharmacotherapy Target For
(12) United States Patent (10) Patent No.: US 8,916,564 B2 Pettersson Et Al
Nicotinic Acetylcholine Receptors: Diversity and Physiological Importance for Neurodegenerative Disorders and Development of Organophosphate Antidotes
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
That the Ultimate
Customs Tariff - Schedule
Probing the Role of Neuronal Nicotinic Acetylcholine Receptors in Modulating in Vitro Hippocampal Network Dynamics
Therapeutic Potential of A7 Nicotinic Acetylcholine Receptors
Pharmaabkommen A1 E
Targacept, Inc. (Exact Name of Registrant As Specified in Its Charter)
Customs Tariff - Schedule Xxi - 1
What Is Plan B If A-Beta Alzheimer's Hypothesis Is Void?
WO 2012/088441 Al 28 June 2012 (28.06.2012) P O P C T
Regulatory Requirements for the Clinical Development of New Therapies for the Treatment of Alzheimer's Disease
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Mechanism Based Pharmacotherapeutic Development and Neurochemistry Involved in Nicotine Dependence Induce Withdrawal Syndrome
Customs Tariff - Schedule
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
New Drug Pipeline Monitor, 6Th Edition DECEMBER 2014
Targeting the Cholinergic System to Develop a Novel Therapy for Huntington’S Disease
Older Americans Affecting Diseases Chronic Top
Construction of SH-EP1-A4b2-Happ695 Cell Line and Effects of Nicotinic Agonists on B-Amyloid in the Cells